Anti-NGF Drugs Clinical Holds Could Depend On What FDA Panel Thinks Of Standard Of Care

FDA’s Arthritis Advisory Committee will review troubling reports that the drugs, meant to relieve chronic pain from osteoarthritis and other diseases, may also destroy patients’ joints.